Docket Management
Docket: 00N-1256 - Over-the-Counter Products
Comment Number: EC -38

Accepted - Volume 6

Comment Record
Commentor Ms. Melinda Arnold Date/Time 2000-06-27 14:33:30
Organization Ms. Melinda Arnold
Category Individual

Comments for FDA General
1. General Comments By allowing drugs such Mevacor and Claritin to be classified as OTC products will definitely improve accessibility for the consumer and eliminate the need for an otherwise meaningless trip to the doctor, both of which will lower insurance costs. I realize that the drug companies producing these drugs will resist this change, and indeed, lobby heavily against it, but the FDA has the authority to override these objections in the best interest of the public. I cannot justify continuing the prescription-only status for drugs such as these simply because the drug companies opine the necessity for frequent doctor visits to maintain the patient's status. Of course, the drug companies market their philosophy to consumers as well as doctors in order to increase their profitability, so the drug company's representatives extol the same reasoning to the doctors, who, in turn, buy into the same reasoning. Profitability. The bottom line is just that ... the bottom line ... and that is the sole goal of the drug companies. The FDA must carefully weigh the merits of consumer availability and cost effectiveness as well as a particular drug's effects. Yours is a burdensome task, but the consumer has no other alternative than to seek relief from the high costs of useful drugs and inflated drug companies than through the auspices of the FDA. Please look out for the consumer.

EC -38